MIPS # 462 Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy
MEASURE DESCRIPTION
Patients determined as having prostate cancer who are currently starting or undergoing androgen deprivation therapy (ADT), for an anticipated period of 12 months or greater and who receive an initial bone density evaluation. The bone density evaluation must be prior to the start of ADT or within 3 months of the start of ADT.
Relevance to Value Based Care
Androgen suppression as a treatment for prostate cancer can cause osteoporosis. Men undergoing prolonged androgen deprivation therapy (ADT) incur bone loss at a rate higher than menopausal women. In preserving bone health, the goal is to prevent or treat osteopenia/osteoporosis for the patient on ADT and to prevent or delay skeletal related events. The National Osteoporosis Foundation recommendations including a baseline assessment of bone density with a DEXA scan and daily calcium and Vitamin D supplementation.
Numerator
Patients with a bone density evaluation within the two years prior to the start of or less than three months after the start of ADT treatment
Denominator
Male patients with a qualifying encounter in measurement period AND with diagnosis of prostate cancer AND with an order for ADT or active medication of ADT with intent for treatment greater than or equal to 12 months during the measurement period
Exclusion/Exceptions
Patient refused bone density evaluation
Scoring
CMS has removed the benchmark for this measure for 2024. Reporting this measure will earn 0 points, unless CMS develops benchmarks after submission.
RESOURCES